New research provides a snapshot of how the advent of rituximab (Rituxan, Genentech) has changed the occurrence of subsequent primary malignancies (SPMs) among lymphoma survivors. The investigators found that, among patients with diffuse large B-cell lymphoma (DLBCL), the risk for acute myeloid leukemia (AML) nearly doubled after rituximab was introduced. The risk for liver, thyroid, head and neck, and kidney cancers also increased, while the likelihood of other cancers decreased.
“This